Jove
Visualize
联系我们

相关概念视频

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

27
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
27
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

20
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
20
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

80
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
80
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

53
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
53
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

47
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
47
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  2. 通过导管进行边缘到边缘的修复,以治疗次要腹 - - Crt 2025超出指南范围
  1. 首页
  2. 通过导管进行边缘到边缘的修复,以治疗次要腹 - - Crt 2025超出指南范围

相关实验视频

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K

通过导管进行边缘到边缘的修复,以治疗次要腹 - - CRT 2025超出指南范围

Dan Haberman1, Michael J Reardon2, Gregg W Stone3

  • 1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Cardiovascular revascularization medicine : including molecular interventions
|September 6, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

在心力衰竭 (HF) 中,次要腹 (SMR) 是常见且严重的. 新证据表明,跨导管边缘修复 (TEER) 可能会使更多的患者超出目前的指导方针.

关键词:
心脏衰竭在 M-TEER中心吐

更多相关视频

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.8K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:02

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

177

相关实验视频

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.8K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:02

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

177

科学领域:

  • 心脏病学
  • 干预心脏病学
  • 心脏衰竭的治疗方法

背景情况:

  • 二次腹 (SMR) 是心力衰竭 (HF) 的常见并发症.
  • 尽管有指导治疗 (GDMT) 和心脏再同步治疗,但SMR显著恶化预后.
  • 目前的指导方针将跨导管边缘修复 (TEER) 限制在严重的耐火性SMR上.

研究的目的:

  • 审查目前的证据和专家意见,以扩大SMR的TEER指示.
  • 确定SMR管理的知识缺口和未来研究方向.
  • 为即将修订的SMR治疗指南提供信息.

主要方法:

  • 在2025年心血管研究技术会议上的专家小组讨论.
  • 最近的关键随机对照试验 (RESHAPE- HF2,MATTERHORN,EFFORT) 的综述
  • 在不同临床场景中分析新出现的证据.

主要成果:

  • 关于中度SMR,无症状患者和特定HF子集的TEER存在未解决的问题.
  • 在更广泛的人群中,注册和观察数据表明TEER的程序安全性和临床益处.
  • 共识支持在特定的SMR子组进行专门试验的必要性.

结论:

  • 现有的指导方针可能不完全涵盖TEER在SMR中的演变作用.
  • 需要进一步的随机试验来澄清中度和无症状SMR中的TEER疗效.
  • 基于现实世界的数据,对TEER进行更广泛的考虑是有必要的.